A new device promising to unlock the health benefits of the sun in just five minutes a week has attracted significant capital. Solius Labs, the company behind an FDA-cleared over-the-counter UVB light therapy device, has closed a $23.0M Series A funding round.
Solius Labs' technology analyzes unique skin tones to deliver a precise, optimal dose of UVB light, aiming to stimulate natural health benefits with less than 1% of the total UV risk. The company plans to bring its personalized, on-demand UVB light therapy into homes and professional wellness settings, with a launch targeted for Summer 2026.
